ArticleAmerican journal of translational research2025
Comprehensive investigation into the preventive and therapeutic efficacy and underlying mechanisms of phycocyanin in diabetic retinopathy in rats.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the protective effects of phycocyanin (PC) on diabetic retinopathy (DR) in a rat model and explore its underlying mechanisms.
methodsMale Sprague-Dawley rats aged 6-8 weeks were used to establish a diabetes model through a high-fat and high-sugar diet followed by intraperitoneal injection of streptozotocin. The rats were randomly divided into the normal, model, and PC groups (n=9). The PC group received a daily oral gavage of 35 mg/kg PC, while the normal and model groups received an equal amount of drinking water. The animals were sacrificed at 8, 12, and 16 weeks after intervention to collect samples. General conditions, body weight, blood glucose levels, retinal morphology, expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and vascular endothelial growth factor (VEGF) proteins, and levels of interleukin-6 (IL-6) and tumor-necrosis factor-alpha (TNF-α) in serum were assessed.
resultsPC significantly improved the symptoms and signs of diabetic rats; alleviated polydipsia, polyphagia, polyuria, and weight loss; and reduced the incidence of diabetic cataracts. After intervention, the rats in the PC group showed significant improvements in body weight and fasting blood glucose levels compared with the model group (P<0.01). Hematoxylin-eosin staining of retinal sections revealed that PC inhibited retinal damage, mitigated the reduction of cell numbers in the inner and outer nuclear layers, and significantly restored retinal thickness at week 16 (P<0.01). Immunohistochemical staining showed that PC significantly reduced the overexpression of NF-κB and VEGF in the retina (P<0.05). Enzyme-linked immunosorbent assay results indicated that PC significantly decreased the serum levels of IL-6 and TNF-α (P<0.01).
conclusionPC exerts protective effects against DR by mitigating inflammatory responses and modulating the expression of NF-κB and VEGF, suggesting its potential as a therapeutic agent for DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.